Treatment of hypertension in diabetes: What is the best therapeutic option?

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 6, 2012, Pages 727-734

  Aksnes, Tonje A ^a   Skårn, Sigrid N ^a   Kjeldsen, Sverre E ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

blockers; ACE inhibitors; angiotensin II type 1 receptor blockers; antihypertensive agents; blood pressure; calcium channel blockers; diabetes mellitus; diuretics; hypertension

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ATENOLOL; BENAZEPRIL; BRADYKININ; CHLORTALIDONE; DOXAZOSIN; EPLERENONE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; NIFEDIPINE; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; DIABETIC HYPERTENSION; DIET RESTRICTION; DISEASE SEVERITY; EXERCISE; FLUID RETENTION; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; META ANALYSIS; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM RESTRICTION; STROKE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; LIFE STYLE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84865220984     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.59     Document Type: Review

References (37)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16(2), 434-444 (1993).
3. Sarwar N, Gao P, Seshasai SR et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375(9733), 2215-2222 (2010).
4. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and Type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur. Heart J. 28(24), 3059-3066 (2007).
5. Norhammar A, Malmberg K, Diderholm E et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J. Am. Coll. Cardiol. 43(4), 585-591 (2004).
6. Malmberg K, Rydén L, Wedel H et al.; DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur. Heart J. 26(7), 650-661 (2005).
7. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229-234 (1998).
8. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension 57(5), 891-897 (2011).
9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28(12), 1462-1536 (2007).
10. Chobanian AV, Bakris GL, Black HR et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003).
11. Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121-2158 (2009).
12. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351(9118), 1755-1762 (1998).
13. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N. Engl. J. Med. 359(15), 1565-1576 (2008).
14. Cushman WC, Evans GW, Byington RP et al.; ACCORD Study Group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1575-1585 (2010).
15. Redon J, Mancia G, Sleight P et al.; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J. Am. Coll. Cardiol. 59(1), 74-83 (2012).
16. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with Type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 123(24), 2799-2819 (2011).
17. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 33(2), 434-441 (2010).
18. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am. J. Clin. Nutr. 65(Suppl. 2), 643S-651S (1997).
19. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann. Intern. Med. 136(7), 493-503 (2002).
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997 (2002).
21. Turnbull F, Neal B, Algert C et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165(12), 1410-1419 (2005).
22. McFarlane SI, Castro J, Kaur J et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J. Clin. Hypertens. (Greenwich) 7(2), 73-80 (2005).
23. Suh DC, Kim CM, Choi IS, Plauschinat CA, Barone JA. Trends in blood pressure control and treatment among Type 2 diabetes with comorbid hypertension in the United States: 1988-2004. J. Hypertens. 27(9), 1908-1916 (2009).
24. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201-207 (2007).
25. Lindholm LH, Ibsen H, Dahlöf B et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 1004-1010 (2002).
26. Zanchetti A, Julius S, Kjeldsen S et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J. Hypertens. 24(11), 2163-2168 (2006).
27. Yusuf S, Teo KK, Pogue J et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547-1559 (2008).
28. Ostergren J, Poulter NR, Sever PS et al.; ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with Type II diabetes. J. Hypertens. 26(11), 2103-2111 (2008).
29. Whelton PK, Barzilay J, Cushman WC et al.; ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of Type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 165(12), 1401-1409 (2005).
30. Beckett NS, Peters R, Fletcher AE et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358(18), 1887-1898 (2008).
31. Grossman E, Messerli FH. Management of blood pressure in patients with diabetes. Am. J. Hypertens. 24(8), 863-875 (2011).
32. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363(9426), 2049-2051 (2004).
33. Corrao G, Nicotra F, Parodi A et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 58(4), 566-572 (2011).
34. Weber MA, Bakris GL, Dahlöf B et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 16(1), 13-19 (2007).
35. Weber MA, Bakris GL, Jamerson K et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J. Am. Coll. Cardiol. 56(1), 77-85 (2010).
36. Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590), 829-840 (2007).
37. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 414(6865), 782-787 (2001).